DNA damage signalling barrier, oxidative stress and treatment‐relevant DNA repair factor alterations during progression of human prostate cancer. Issue 6 (3rd March 2016)

• Record Type: Journal Article
• Authors: Kurfurstova, Daniela; Bartkova, Jirina; Vrtel, Radek; Mickova, Alena; Burdova, Alena; Majera, Dusana; Mistrik, Martin; Kral, Milan; Santer, Frederic R.; Bouchal, Jan; Bartek, Jiri
• Is Part Of: Molecular oncology. Volume 10:Issue 6(2016:Jun.)
• Page Start: 879
• Page End: 894
• Publication Date: 2016-03-03
• Subjects: Prostate tumorigenesis -- DNA damage response barrier -- p53 and NKX3.1 tumour suppressors -- NQO1 and oxidative stress -- TMPRSS2‐ERG -- PARP inhibitor biomarkers; Cancer -- Molecular aspects -- Periodicals; 616.994005
• DOI: 10.1016/j.molonc.2016.02.005
• Languages: English
• ISSNs: 1574-7891

Abstract

Abstract : The DNA damage checkpoints provide an anti‐cancer barrier in diverse tumour types, however this concept has remained unexplored in prostate cancer (CaP). Furthermore, targeting DNA repair defects by PARP1 inhibitors (PARPi) as a cancer treatment strategy is emerging yet requires suitable predictive biomarkers. To address these issues, we performed immunohistochemical analysis of multiple markers of DNA damage signalling, oxidative stress, DNA repair and cell cycle control pathways during progression of human prostate disease from benign hyperplasia, through intraepithelial neoplasia to CaP, complemented by genetic analyses of TMPRSS2‐ERG rearrangement and NQO1, an anti‐oxidant factor and p53 protector. The DNA damage checkpoint barrier (γH2AX, pATM, p53) mechanism was activated during CaP tumorigenesis, albeit less and with delayed culmination compared to other cancers, possibly reflecting lower replication stress (slow proliferation despite cases of Rb loss and cyclin D1 overexpression) and progressive loss of ATM activator NKX3.1. Oxidative stress (8‐oxoguanine lesions) and NQO1 increased during disease progression. NQO1 genotypes of 390 men did not indicate predisposition to CaP, yet loss of NQO1 in CaP suggested potential progression‐opposing tumour suppressor role. TMPRSS2‐ERG rearrangement and PTEN loss, events sensitizing to PARPi, occurred frequently along with heterogeneous loss of DNA repair factors 53BP1, JMJD1C and Rev7 (all studied here for the first time in CaP) whose defects may cause resistance to PARPi. Overall, our results reveal an unorthodox DNA damage checkpoint barrier scenario in CaP tumorigenesis, and provide novel insights into oxidative stress and DNA repair, with implications for biomarker guidance of future targeted therapy of CaP. Highlights: Activated ATM, γH2AX and p53 'checkpoint' increases during prostate tumorigenesis. Prostate DNA damage checkpoint barrier is delayed and less pronounced than in other cancers. Oxidative stress and NQO1 levels increase with human prostate lesion progression. NKX3.1 or DNA repair factors 53BP1, JMJD1C, Rev7 show focal loss in prostate cancer. TMPRSS2‐ERG gain, loss of PTEN and DNA repair factors may help to predict response to PARP inhibitors.